UNSPSC 51241105: Carbachol

This classification denotes an anti-glaucoma agent with the molecular formula C6H15N2O2.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y164V895Y, chemically known as 2-((aminocarbonyl)oxy)-n,n,n-trimethylethanaminium but generally known as carbachol, which bears US NIH Compound Identifier 2551. Carbachol most often comes in base, chloride, and hydrochloride forms. European Medicines Agency schedules Carbachol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06087MIG.

UNSPSC 51241105 Carbachol is a Commodity code representing pharmaceutical active ingredients and finished pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments buy carbachol and other generic multi-source pharmaceuticals through statewide and multistate cooperative contracts that establish pricing, supply chain relationships, and distribution networks to member agencies including health departments, correctional facilities, and other state and local entities. The work involves manufacturer submissions of detailed product specifications (National Drug Codes, SKUs, UPCs, dosage forms, packaging configurations), compliance certifications (cGMP, Drug Supply Chain Security Act), and pricing structures negotiated with authorized pharmaceutical wholesalers. Issuing bodies under this code include state procurement offices administering multistate cooperative purchasing alliances and the member states and local jurisdictions participating in those agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the most recent representative opportunity on January 20, 2026—an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The contract spans participating state and local government facilities across Minnesota, Oregon, and other MMCAP member states, with awarded vendors required to supply through three designated wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson) by the July 1, 2026 contract effective date. Vendors must maintain $5 million commercial general liability coverage, $2 million network security and privacy liability, and $2 million professional liability; certify cGMP and DSCSA compliance; and offer pricing flexibility through flat-fee, net-price, or WAC-minus structures. The evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Contract terms run two years for new vendors with optional extensions, or through June 30, 2028 for incumbent vendors.